Processing

Please wait...

Settings

Settings

Goto Application

1. WO2007092471 - METHODS FOR INHIBITION OF LYMPHANGIOGENESIS AND TUMOR METASTASIS

Publication Number WO/2007/092471
Publication Date 16.08.2007
International Application No. PCT/US2007/003205
International Filing Date 05.02.2007
IPC
G01N 33/53 2006.01
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53Immunoassay; Biospecific binding assay; Materials therefor
G01N 33/567 2006.01
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53Immunoassay; Biospecific binding assay; Materials therefor
566using specific carrier or receptor proteins as ligand binding reagent
567utilising isolate of tissue or organ as binding agent
G01N 33/574 2006.01
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53Immunoassay; Biospecific binding assay; Materials therefor
574for cancer
A61K 39/395 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
CPC
A61K 2039/505
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
505comprising antibodies
C07K 16/2842
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
2839against the integrin superfamily
2842against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
C07K 2317/76
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
2317Immunoglobulins specific features
70characterized by effect upon binding to a cell or to an antigen
76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Applicants
  • THE REGENTS OF THE UNIVERSITY OF CALIFORNIA [US]/[US] (AllExceptUS)
  • VARNER, Judith, A. [US]/[US] (UsOnly)
  • GARMY-SUSINI, Barbara [FR]/[US] (UsOnly)
Inventors
  • VARNER, Judith, A.
  • GARMY-SUSINI, Barbara
Agents
  • LEKUTIS, Christine, A.
Priority Data
60/765,06803.02.2006US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) METHODS FOR INHIBITION OF LYMPHANGIOGENESIS AND TUMOR METASTASIS
(FR) PROCÉDÉS D'INHIBITION DE LYMPHANGIOGÉNÈSE ET DE MÉTASTASE TUMORALE
Abstract
(EN)
The present invention is directed to compositions and methods for inhibiting the development of new lymphatic vessels, and for inhibiting tumor cell dissemination through the lymphatics. In preferred embodiments, the present invention utilizes agents that inhibit the specific binding of integrin alpha4beta1 (α4βl, VLA-4) to one or more of its ligands. The invention further relates to methods for screening test compounds for their ability to inhibit undesirable lymphangiogenesis and/or tumor metastasis.
(FR)
La présente invention concerne des compositions et des procédés d'inhibition du développement de nouveaux vaisseaux lymphatiques et d'inhibition de la dissémination de cellules tumorales par le biais du système lymphatique. Dans des modes de réalisation préférés, la présente invention conerne l'utilisation d'agents qui inhibent la liaison spécifique d'intégrine alpha4béta1 (α4βl, VLA-4) à au moins un de ses ligands. L'invention a en outre trait à des procédés de dépistage de composés de test pour leur habilité à inhiber une lymphangiogénèse et/ou une métastase tumorale indésirable.
Also published as
Latest bibliographic data on file with the International Bureau